Document is current

Any future updates will be listed below

Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma

Crossref DOI link: https://doi.org/10.1038/s41416-025-03077-3

Published Online: 2025-08-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark